This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investors Twice Shy on Cell Therapeutics

Punk Ziegel biotech analyst Matt Kaplan believes that the Stellar 3 delay does suggest that positive data are coming. He combed medical journals and found 10 studies involving similar lung cancer patients with performance status 2 who were treated with various combinations of chemotherapy drugs. In these studies, median survival fell typically into the four-to-five month range.

The last patient enrolled in the Stellar 3 trial in November 2003, so given an anticipated early 2005 data release, Kaplan believes this suggests that Xyotax is having a positive impact on survival. Kaplan rates Cell Therapeutics a buy with an $18 price target. His firm has a banking relationship with the company.

But yet, investors haven't responded at all. The stock is actually down from when Cell Therapeutics first started dropping bullish hints about Stellar 3 in May.

"My guess from an investor standpoint is that in the absence of any near-term data, investors are not willing to give Cell Therapeutics the benefit of the doubt, especially when management has a history of disappointing," said Lehman Brothers analyst Jim Birchenough.

The biggest disappointment so far, he says, is the company's failure to follow through on a much-hyped promise to ink a Big Pharma marketing partnership for Xyotax. Birchenough downgraded Cell Therapeutics to equal weight from overweight in June 2003, when instead of announcing an expected Xyotax deal, the company ventured over to Europe to acquire Novuspharma, a rather obscure Italian biotech firm that had been on the sale block for months, with no takers. (Birchenough's firm doesn't do banking for Cell Therapeutics.)

Indeed, a look at Cell Therapeutics' chart shows that its stock hit the skids the day the Novuspharma acquisition was announced on June 17, 2003. The previous day, the stock hit an intraday high of $15.70 -- it hasn't been anywhere close to that since.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
TELK $2.75 -8.33%
CTIC $1.82 0.00%
BMY $65.35 0.00%
AAPL $124.75 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs